Vasoactive intestinal peptide as a bronchodilator in severe asthma

Citations of this article
Mendeley users who have this article in their library.
Get full text


In two studies vasoactive intestinal peptide (VIP) was administered intravenously to two groups of eight in-patient volunteers recovering from severe acute asthma. VIP (6 pmol/kg/min) infusion caused significant (p<0.01) increase in peak expiratory flow rate (PEFR) of 26±9 (SEM) l/min after 30 minutes infusion compared with a bronchodilation of 39±19 l/min seen with salbutamol (5 mcg/min). Following pretreatment with nebulized ipratropium bromide, VIP infusion caused a significant (p<0.02) bronchodilation of 25 l/min. VIP is a broncholdilator in severe asthma, although its effects are less than conventional medication. Reflex mechanisms are unlikely to explain the bronchodilatory effect of intravenous VIP. © 1986.

Author supplied keywords




Morice, A. H., & Sever, P. S. (1986). Vasoactive intestinal peptide as a bronchodilator in severe asthma. Peptides, 7(SUPPL. 1), 279–280.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free